A mutual regulatory loop between miR-155 and SOCS1 influences renal inflammation and diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Molecular Biology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes, driven by hyperglycemia and inflammation.
• The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is implicated in DKD pathogenesis.
• MicroRNA-155 (miR-155) is involved in diabetes complications, but its role in DKD is not fully understood.

Purpose of the Study:

• To investigate the role of miR-155-5p and its interaction with suppressor of cytokine signaling 1 (SOCS1) in regulating the JAK/STAT pathway in DKD.
• To explore the therapeutic potential of modulating the miR-155/SOCS1 axis for DKD treatment.

Main Methods:

• Utilized gain- and loss-of-function experiments in renal cells and diabetic mouse models.
• Assessed miR-155-5p and SOCS1 expression, JAK/STAT pathway activation, cytokine levels, and markers of kidney injury (e.g., albuminuria).
• Investigated the effects of miR-155-5p inhibition and SOCS1 overexpression/gene delivery.

Main Results:

• miR-155-5p expression inversely correlated with SOCS1 and positively with kidney damage markers and inflammation in DKD models.
• miR-155-5p promoted JAK/STAT activation and inflammation, while its inhibition or SOCS1 overexpression conferred protection.
• Therapeutic inhibition of miR-155-5p or SOCS1 gene delivery reduced kidney injury in diabetic mice.

Conclusions:

• The miR-155/SOCS1 axis plays a critical role in regulating renal inflammation and damage in DKD.
• Modulating this axis, particularly by inhibiting miR-155-5p, offers a promising therapeutic strategy for DKD.
• Targeting the miR-155/SOCS1 interaction presents a novel therapeutic avenue for managing diabetic kidney disease.